连续血糖监测时间序列分析预测2型糖尿病疗效
研究纳入111例2型糖尿病门诊患者,在降糖治疗开始时进行14天连续血糖监测,通过时间序列聚类提取趋势成分生成代表性血糖谱,并据此分组预测6个月疗效。结果显示,血糖趋势下降组、上升组和不变组的空腹血糖与糖化血红蛋白变化存在显著差异(P < 0.01),提示CGM趋势聚类可预测治疗反应。
要点
- CGM趋势成分聚类可生成代表性血糖谱并预测6个月降糖疗效。
- 趋势下降组空腹血糖降幅最大,上升组反而升高。
- 三组间糖化血红蛋白变化差异有统计学意义(P < 0.01)。
核心结论
- CGM数据趋势成分聚类生成的代表性血糖谱可预测2型糖尿病6个月治疗效果。
研究设计与样本
- 研究纳入111例宁波市第一医院2型糖尿病门诊患者,治疗开始时进行14天CGM测量,每日96次,共960至1344次测量。
- 采用时间序列聚类方法提取CGM趋势成分生成代表性血糖谱,据此将患者分组并预测疗效。
主要发现
- 患者被分为趋势下降组47例、上升组26例和不变组38例。
- 治疗6个月后,下降组空腹血糖从10.2降至6.8 mmol/L(降3.4 mmol/L),上升组从8.9升至9.2 mmol/L(升0.3 mmol/L),不变组从8.4降至7.5 mmol/L(降0.9 mmol/L)。
- 三组糖化血红蛋白变化分别为2.3%、0.2%和0.9%(P < 0.01)。
临床怎么用
- 对2型糖尿病降糖治疗起始患者,可考虑用14天CGM趋势聚类生成的代表性血糖谱辅助预判6个月疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: There is a challenge to predict treatment effects in patients with type 2 diabetes mellitus (T2DM). OBJECTIVE: To assess and predict treatment effects in patients with T2DM through time-series analysis of continuous glucose monitoring (CGM) measurements. METHOD: We extracted and clustered the trend components of CGM measurements to generate representative time-series profiles, which were used as a predictor of treatment effects in groups of patients. SETTING AND PARTICIPANTS: We recruited 111 outpatients with T2DM at Ningbo City First Hospital, China. INTERVENTION: The patients underwent CGM measurement for 14 days at the beginning of glucose-lowering treatment. MAIN OUTCOME MEASURES: Hemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) were obtained at the beginning and after 6 months of treatment. RESULTS: 111 patients each had 960 to 1344 CGM measurements for 14 days at 96 measurements per day. The patients were classified into 3 groups according to the profiles of trend components of CGM observed values by time-series clustering method, including decreasing (47 patients), increasing (26 patients), and unchanged (38 patients) profiles. After 6 months of glucose-lowering treatment, FPG declined from 10.2 to 6.8 mmol/L (a decline of 3.4 mmol/L) in the decreasing group, from 8.9 to 9.2 mmol/L (a rise of 0.3 mmol/L) in the increasing group, and from 8.4 to 7.5 mmol/L (a decline of 0.9 mmol/L) in the unchanged group. The changes of HbA1c were 2.3%, 0.2%, and 0.9% for the 3 groups (P < 0.01), respectively. CONCLUSIONS: Clustering of the trend components of CGM data generates representative CGM profiles that are predictive of 6-month therapeutic effects for T2DM.
引用
- Li L, Sun J, Ruan L, et al. Time-Series Analysis of Continuous Glucose Monitoring Data to Predict Treatment Efficacy in Patients with T2DM. J Clin Endocrinol Metab. 2021. PMID: 34010405. doi:10.1210/clinem/dgab356
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。